Personalis (NASDAQ:PSNL) Shares Down 4.8% – Time to Sell?

Personalis, Inc. (NASDAQ:PSNL)’s stock price was down 4.8% during mid-day trading on Friday . The stock traded as low as $8.38 and last traded at $8.4780. Approximately 194,504 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,274,530 shares. The stock had previously closed at $8.91.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PSNL. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Lake Street Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Personalis in a research note on Wednesday, November 5th. Needham & Company LLC boosted their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Guggenheim increased their price target on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, HC Wainwright raised their price target on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.86.

Personalis Stock Down 7.1%

The company has a market capitalization of $735.26 million, a PE ratio of -9.41 and a beta of 1.98. The business has a 50 day simple moving average of $8.78 and a 200 day simple moving average of $7.84.

Insiders Place Their Bets

In other news, CFO Aaron Tachibana sold 103,668 shares of Personalis stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in shares of Personalis in the second quarter worth about $30,000. International Assets Investment Management LLC acquired a new position in Personalis in the 4th quarter worth approximately $31,000. Ameritas Investment Partners Inc. purchased a new position in Personalis during the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its stake in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after acquiring an additional 3,592 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.